Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine. Issue 1 (24th October 2019)

• Record Type: Journal Article
• Authors: Hassannia, Hadi; Ghasemi Chaleshtari, Mitra; Atyabi, Fatemeh; Nosouhian, Mahshid; Masjedi, Ali; Hojjat‐Farsangi, Mohammad; Namdar, Afshin; Azizi, Gholamreza; Mohammadi, Hamed; Ghalamfarsa, Ghasem; Sabz, Gholamabas; Hasanzadeh, Sajad; Yousefi, Mehdi; Jadidi‐Niaragh, Farhad
• Is Part Of: Immunology. Volume 159:Issue 1(2020)
• Page Start: 75
• Page End: 87
• Publication Date: 2019-10-24
• Subjects: cancer immunotherapy -- dendritic cell vaccine -- nanoparticle -- programmed cell death protein 1 -- programmed death ligand 1; Immunology -- Periodicals
• DOI: 10.1111/imm.13126
• Languages: English
• ISSNs: 0019-2805

Abstract

Summary: Dendritic cell (DC) ‐based cancer immunotherapy is one of the most important anti‐cancer immunotherapies, and has been associated with variable efficiencies in different cancer types. It is well‐known that tumor microenvironment plays a key role in the efficacy of various immunotherapies such as DC vaccine. Accordingly, the expression of programmed death ligand 1 (PD‐L1) on DCs, which interacts with PD‐1 on T cells, leads to inhibition of anti‐tumor responses following presentation of tumor antigens by DCs to T cells. Therefore, we hypothesized that down‐regulation of PD‐L1 in DCs in association with silencing of PD‐1 on T cells may lead to the enhancement of T‐cell priming by DCs to have efficient anti‐tumor T‐cell responses. In this study, we silenced the expression of PD‐L1 in DCs and programmed cell death protein 1 (PD‐1) in T cells by small interfering RNA (siRNA) ‐loaded chitosan–dextran sulfate nanoparticles (NPs) and evaluated the DC phenotypic and functional characteristics and T‐cell functions following tumor antigen recognition on DCs, ex vivo . Our results showed that synthesized NPs had good physicochemical characteristics (size 77·5 nm and zeta potential of 14·3) that were associated with efficient cellular uptake and target gene silencing. Moreover, PD‐L1 silencing was associated with stimulatory characteristics of DCs. On the other hand, presentation of tumor antigens by PD‐L1‐negative DCs to PD‐1‐silenced T cells led to induction of potent T‐cell responses. Our findings imply that PD‐L1‐silenced DCs can be considered as a potent immunotherapeutic approach in combination with PD‐1‐siRNA loaded NPs, however; further in vivo investigation is required in animal models. Abstract : Expression of PD‐L1 on DCs inhibits their function. PD‐1 on T cells disrupts T cell function. Concomitant silencing of PD‐L1 and PD‐1 can induce potent anti‐tumor immune responses.